Compare KraneShares CSI China Internet ETF (KWEB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Viatris Inc — how do they compare? KraneShares CSI China Internet ETF trades at $27.08, while Viatris Inc trades at $17.32 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while KraneShares CSI China Internet ETF pays none, and Viatris Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| KWEB | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.94 | $17.39 |
52-Week Low | $23.63 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $27.44, up 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers exposure to leading Chinese internet and AI companies, currently near 52-week lows. Recent news highlights China's AI investment plans and factory rebound driven by AI hardware exports, providing potential growth catalysts amid economic stabilization efforts.
The outlook for KWEB is cautiously optimistic, with attractive valuations relative to Western peers and strong AI-driven growth potential. Key risks include US-China tensions, regulatory changes, and economic volatility. Analyst sentiment is mixed, balancing long-term value against near-term geopolitical and market uncertainties.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
